How to Buy balaxi Shares on Fincept?
You can buy Balaxi Pharmaceuticals Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Balaxi Pharmaceuticals Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Balaxi, including updates on board meetings and corporate actions.
Balaxi Pharmaceuticals Limited - https://balaxipharma.in
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. The company offers pharmaceutical products across various therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes. The company was formerly known as Balaxi Ventures Limited and changed its name to Balaxi Pharmaceuticals Limited in October 2020. Balaxi Pharmaceuticals Limited was incorporated in 1942 and is headquartered in Hyderabad, India. Balaxi Pharmaceuticals Limited is a subsidiary of Balaxi Overseas Private Limited.
Balaxi Pharmaceuticals Limited Share Price Today
69.00
OPEN
70.98
HIGH
62.78
LOW
64.21
CLOSE
49 K
VOLUME
388 Cr
Market Cap
34625
Average Volume
Healthcare
Sector
NSI
Exchange
Balaxi Pharmaceuticals Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: BALAXI Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
BALAXI PHARMACEUTICALS LIMITED |
BALAXI |
INE618N01014 |
Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share |
30 May 2024 |
2 |
N/A |
BALAXI PHARMACEUTICALS LIMITED |
BALAXI |
INE618N01014 |
Annual General Meeting/Dividend - Rs 0.50 Per Share |
01 Jul 2022 |
2 |
N/A |
NSE: BALAXI Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
BALAXI |
30 Dec 2024, 14:53:44 |
Trading Window-XBRL |
N/A |
BALAXI |
30 Dec 2024, 14:24:28 |
Trading Window |
N/A |
BALAXI |
15 Nov 2024, 15:36:38 |
Credit Rating |
N/A |
BALAXI |
13 Nov 2024, 17:11:36 |
Investor Presentation |
N/A |
BALAXI |
07 Nov 2024, 18:28:17 |
Shareholders meeting |
N/A |
NSE: BALAXI Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
BALAXI PHARMACEUTICALS LIMITED |
BALAXI |
17 Oct 2024, 10:29:00 |
17 Oct 2024, 10:29:00 |
|
BALAXI PHARMACEUTICALS LIMITED |
BALAXI |
17 Jul 2024, 16:56:00 |
17 Jul 2024, 16:56:00 |
|
BALAXI PHARMACEUTICALS LIMITED |
BALAXI |
06 Apr 2024, 12:53:00 |
06 Apr 2024, 13:15:00 |
|
BALAXI PHARMACEUTICALS LIMITED |
BALAXI |
02 Jan 2024, 12:45:00 |
02 Jan 2024, 13:15:00 |
|
BALAXI PHARMACEUTICALS LIMITED |
BALAXI |
11 Oct 2023, 11:01:00 |
11 Oct 2023, 11:30:00 |
NSE: BALAXI Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson & Executive Director-MD |
20 Apr 1970 |
04 May 2017 |
01575984 |
Ashish Maheshwari |
Active |
Non-Executive Director |
08 Jul 1972 |
04 May 2017 |
01575975 |
Minoshi Maheshwari |
Active |
Independent Director |
10 Jan 1982 |
04 May 2017 |
01710557 |
Kunal Mahendra Bhakta |
Active |
Independent Director |
12 Oct 1969 |
04 May 2017 |
01944694 |
Gandhi Gamji |
Active |
Independent Director |
09 Aug 1960 |
15 Sep 2020 |
08095079 |
M Srinivas Rao |
Active |
NSE: BALAXI Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
Board Meeting Intimation |
BALAXI |
N/A |
INE618N01014 |
BALAXI PHARMACEUTICALS LIMITED |
29 Oct 2024, 16:31:40 |
Financial Results |
BALAXI |
N/A |
INE618N01014 |
BALAXI PHARMACEUTICALS LIMITED |
25 Jul 2024, 14:36:41 |
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 29-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Other business. |
BALAXI |
N/A |
INE618N01014 |
BALAXI PHARMACEUTICALS LIMITED |
21 May 2024, 14:21:45 |
Stock Split |
BALAXI |
N/A |
INE618N01014 |
BALAXI PHARMACEUTICALS LIMITED |
09 Feb 2024, 13:31:02 |
BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 09-Feb-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended December 2023 and Other business. |
BALAXI |
N/A |
INE618N01014 |
BALAXI PHARMACEUTICALS LIMITED |
02 Feb 2024, 13:20:03 |
NSE: BALAXI Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results/Other business matters |
BALAXI |
- |
INE618N01014 |
BALAXI PHARMACEUTICALS LIMITED |
29 Oct 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 and other business matters |
Financial Results |
BALAXI |
- |
INE618N01014 |
BALAXI PHARMACEUTICALS LIMITED |
25 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Financial Results |
BALAXI |
- |
INE618N01014 |
BALAXI PHARMACEUTICALS LIMITED |
21 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024 |
Stock Split |
BALAXI |
- |
INE618N01014 |
BALAXI PHARMACEUTICALS LIMITED |
09 Feb 2024, 00:00:00 |
To consider stock split of equity shares |
Financial Results/Other business matters |
BALAXI |
- |
INE618N01014 |
BALAXI PHARMACEUTICALS LIMITED |
02 Feb 2024, 00:00:00 |
To consider and approve the financial results for the period ended December 31, 2023 and other business matters |
NSE: BALAXI Balance Sheet Data In (Cr)
| date | period_type | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Stockholders Equity | Other Equity Interest | Fixed Assets Revaluation Reserve | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Deferred Taxes Liabilities | Current Debt And Capital Lease Obligation | Current Debt | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Investmentin Financial Assets | Available For Sale Securities | Long Term Equity Investment | Investmentsin Subsidiariesat Cost | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Properties | Current Assets | Other Current Assets | Prepaid Assets | Inventory | Finished Goods | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 0.00 | 0.00 | 0.00 | 321,024,000.00 | 1,896,435,000.00 | 2,461,985,000.00 | 1,698,929,000.00 | 1,896,435,000.00 | 17,721,000.00 | 2,158,682,000.00 | 2,158,682,000.00 | 2,158,682,000.00 | 2,158,682,000.00 | 2,048,267,000.00 | 0.00 | 0.00 | 0.00 | 110,415,000.00 | 110,415,000.00 | 720,971,000.00 | 27,727,000.00 | 0.00 | 9,573,000.00 | 17,721,000.00 | 17,721,000.00 | 0.00 | 433,000.00 | 693,244,000.00 | 35,934,000.00 | 0.00 | 303,303,000.00 | 303,303,000.00 | 42,213,000.00 | 311,794,000.00 | 0.00 | 0.00 | 0.00 | 311,794,000.00 | 2,879,653,000.00 | 487,480,000.00 | 55,760,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 262,247,000.00 | 0.00 | 262,247,000.00 | 169,473,000.00 | 169,473,000.00 | 0.00 | 169,473,000.00 | 0.00 | 0.00 | 0.00 | 2,392,173,000.00 | 86,503,000.00 | 0.00 | 851,296,000.00 | 0.00 | 33,089,000.00 | 0.00 | 812,614,000.00 | 0.00 | 0.00 | 608,671,000.00 | 608,671,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 54,488,750.00 | 54,488,750.00 | 0.00 | 194,041,000.00 | 1,744,855,000.00 | 2,190,248,000.00 | 1,559,747,000.00 | 1,744,855,000.00 | 17,432,000.00 | 2,013,639,000.00 | 2,013,639,000.00 | 2,013,639,000.00 | 2,013,639,000.00 | 37,728,000.00 | 0.00 | 1,358,034,000.00 | 508,438,000.00 | 108,978,000.00 | 108,978,000.00 | 569,793,000.00 | 27,820,000.00 | 1,000.00 | 9,954,000.00 | 17,432,000.00 | 17,432,000.00 | 0.00 | 433,000.00 | 541,973,000.00 | 9,254,000.00 | 28,829,000.00 | 176,609,000.00 | 176,609,000.00 | 28,833,000.00 | 327,281,000.00 | 36,850,000.00 | 47,000.00 | 0.00 | 290,384,000.00 | 2,583,432,000.00 | 481,713,000.00 | 49,843,000.00 | 48,793,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 268,784,000.00 | 7,780,000.00 | 261,004,000.00 | 163,085,000.00 | 163,085,000.00 | 23,084,000.00 | 57,291,000.00 | 82,658,000.00 | 52,000.00 | 0.00 | 2,101,720,000.00 | 81,071,000.00 | 68,123,000.00 | 821,680,000.00 | 821,680,000.00 | 19,011,000.00 | 12,948,000.00 | 557,051,000.00 | 0.00 | 557,051,000.00 | 622,907,000.00 | 622,907,000.00 | 0.00 | 622,907,000.00 |
| 2024-03-31T00:00:00 | annual | 54,488,750.00 | 54,488,750.00 | 0.00 | 194,041,000.00 | 1,744,855,000.00 | 2,190,248,000.00 | 1,559,747,000.00 | 1,744,855,000.00 | 17,432,000.00 | 2,013,639,000.00 | 2,013,639,000.00 | 2,013,639,000.00 | 2,013,639,000.00 | 37,728,000.00 | 0.00 | 1,358,034,000.00 | 508,438,000.00 | 108,978,000.00 | 108,978,000.00 | 569,793,000.00 | 27,820,000.00 | 1,000.00 | 9,954,000.00 | 17,432,000.00 | 17,432,000.00 | 0.00 | 433,000.00 | 541,973,000.00 | 9,254,000.00 | 28,829,000.00 | 176,609,000.00 | 176,609,000.00 | 28,833,000.00 | 327,281,000.00 | 36,850,000.00 | 47,000.00 | 0.00 | 290,384,000.00 | 2,583,432,000.00 | 481,713,000.00 | 49,843,000.00 | 48,793,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 268,784,000.00 | 7,780,000.00 | 261,004,000.00 | 163,085,000.00 | 163,085,000.00 | 23,084,000.00 | 57,291,000.00 | 82,658,000.00 | 52,000.00 | 0.00 | 2,101,720,000.00 | 81,071,000.00 | 68,123,000.00 | 821,680,000.00 | 821,680,000.00 | 19,011,000.00 | 12,948,000.00 | 557,051,000.00 | 0.00 | 557,051,000.00 | 622,907,000.00 | 622,907,000.00 | 0.00 | 622,907,000.00 |
| 2023-09-30T00:00:00 | quarterly | 0.00 | 0.00 | 0.00 | 187,339,000.00 | 1,299,809,000.00 | 1,742,054,000.00 | 1,076,096,000.00 | 1,299,809,000.00 | 0.00 | 1,554,715,000.00 | 1,558,731,000.00 | 1,554,715,000.00 | 1,554,715,000.00 | 1,452,413,000.00 | 0.00 | 0.00 | 0.00 | 102,302,000.00 | 102,302,000.00 | 590,003,000.00 | 32,106,000.00 | 0.00 | 10,945,000.00 | 4,016,000.00 | 0.00 | 4,016,000.00 | 17,145,000.00 | 557,897,000.00 | 3,458,000.00 | 0.00 | 183,323,000.00 | 183,323,000.00 | 74,473,000.00 | 296,643,000.00 | 0.00 | 0.00 | 0.00 | 296,643,000.00 | 2,144,718,000.00 | 510,725,000.00 | 78,278,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 254,906,000.00 | 0.00 | 254,906,000.00 | 177,541,000.00 | 177,541,000.00 | 0.00 | 177,541,000.00 | 0.00 | 0.00 | 0.00 | 1,633,993,000.00 | 30,371,000.00 | 0.00 | 852,215,000.00 | 0.00 | 25,413,000.00 | 0.00 | 444,564,000.00 | 0.00 | 0.00 | 281,430,000.00 | 281,430,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 50,906,250.00 | 50,906,250.00 | 0.00 | 133,065,000.00 | 1,567,469,000.00 | 1,945,005,000.00 | 1,403,777,000.00 | 1,567,469,000.00 | 16,858,000.00 | 1,828,798,000.00 | 1,837,495,000.00 | 1,828,798,000.00 | 1,828,798,000.00 | 102,969,000.00 | 0.00 | 1,431,094,000.00 | 192,461,000.00 | 101,813,000.00 | 101,813,000.00 | 567,892,000.00 | 36,560,000.00 | -1,000.00 | 11,005,000.00 | 25,555,000.00 | 16,858,000.00 | 8,697,000.00 | 0.00 | 531,332,000.00 | 8,406,000.00 | 50,566,000.00 | 107,510,000.00 | 107,510,000.00 | 0.00 | 364,850,000.00 | 19,611,000.00 | 47,000.00 | 50,566,000.00 | 345,192,000.00 | 2,396,690,000.00 | 461,580,000.00 | 19,191,000.00 | 18,759,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 261,329,000.00 | 9,094,000.00 | 252,235,000.00 | 181,060,000.00 | 181,060,000.00 | 28,316,000.00 | 59,139,000.00 | 93,307,000.00 | 298,000.00 | 0.00 | 1,935,109,000.00 | 51,978,000.00 | 52,686,000.00 | 1,050,233,000.00 | 1,050,233,000.00 | 16,476,000.00 | 10,726,000.00 | 522,820,000.00 | 0.00 | 522,820,000.00 | 282,168,000.00 | 282,168,000.00 | 0.00 | 282,168,000.00 |
| 2023-03-31T00:00:00 | annual | 50,906,250.00 | 50,906,250.00 | 0.00 | 133,065,000.00 | 1,567,469,000.00 | 1,945,005,000.00 | 1,403,777,000.00 | 1,567,469,000.00 | 16,858,000.00 | 1,828,798,000.00 | 1,837,495,000.00 | 1,828,798,000.00 | 1,828,798,000.00 | 102,969,000.00 | 0.00 | 1,431,094,000.00 | 192,461,000.00 | 101,813,000.00 | 101,813,000.00 | 567,892,000.00 | 36,560,000.00 | -1,000.00 | 11,005,000.00 | 25,555,000.00 | 16,858,000.00 | 8,697,000.00 | 0.00 | 531,332,000.00 | 8,406,000.00 | 50,566,000.00 | 107,510,000.00 | 107,510,000.00 | 0.00 | 364,850,000.00 | 19,611,000.00 | 47,000.00 | 50,566,000.00 | 345,192,000.00 | 2,396,690,000.00 | 461,580,000.00 | 19,191,000.00 | 18,759,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 261,329,000.00 | 9,094,000.00 | 252,235,000.00 | 181,060,000.00 | 181,060,000.00 | 28,316,000.00 | 59,139,000.00 | 93,307,000.00 | 298,000.00 | 0.00 | 1,935,109,000.00 | 51,978,000.00 | 52,686,000.00 | 1,050,233,000.00 | 1,050,233,000.00 | 16,476,000.00 | 10,726,000.00 | 522,820,000.00 | 0.00 | 522,820,000.00 | 282,168,000.00 | 282,168,000.00 | 0.00 | 282,168,000.00 |
| 2022-03-31T00:00:00 | annual | 50,000,000.00 | 50,000,000.00 | 0.00 | 36,381,000.00 | 890,374,000.00 | 1,168,022,000.00 | 777,355,000.00 | 890,374,000.00 | 0.00 | 1,131,641,000.00 | 1,131,641,000.00 | 1,131,641,000.00 | 1,131,641,000.00 | 1,031,642,000.00 | 0.00 | 918,650,000.00 | 112,530,000.00 | 100,000,000.00 | 100,000,000.00 | 633,065,000.00 | 389,000.00 | 1,000.00 | 388,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 632,676,000.00 | 865,000.00 | 72,522,000.00 | 36,381,000.00 | 36,381,000.00 | 72,521,000.00 | 522,908,000.00 | 31,732,000.00 | 31,000.00 | 0.00 | 491,145,000.00 | 1,764,706,000.00 | 354,675,000.00 | 16,685,000.00 | 15,798,000.00 | 44,699,000.00 | 44,699,000.00 | 0.00 | 0.00 | 241,267,000.00 | 8,247,000.00 | 233,020,000.00 | 52,024,000.00 | 52,024,000.00 | 5,720,000.00 | 54,551,000.00 | 45,738,000.00 | 566,000.00 | 0.00 | 1,410,031,000.00 | 277,000.00 | 56,718,000.00 | 987,036,000.00 | 987,036,000.00 | 7,475,000.00 | 11,006,000.00 | 275,590,000.00 | 0.00 | 275,590,000.00 | 71,929,000.00 | 71,929,000.00 | 31,000.00 | 71,929,000.00 |
| 2021-03-31T00:00:00 | annual | 50,000,000.00 | 50,000,000.00 | 19,902,000.00 | 36,592,000.00 | 637,007,000.00 | 686,390,000.00 | 590,776,000.00 | 637,007,000.00 | 0.00 | 649,798,000.00 | 649,798,000.00 | 649,798,000.00 | 649,798,000.00 | 0.00 | 0.00 | 436,807,000.00 | 112,530,000.00 | 100,000,000.00 | 100,000,000.00 | 346,998,000.00 | 67,000.00 | -4,000.00 | 71,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 346,931,000.00 | 1,283,000.00 | 60,118,000.00 | 36,592,000.00 | 36,592,000.00 | 0.00 | 248,938,000.00 | 28,235,000.00 | 125,000.00 | 0.00 | 220,578,000.00 | 996,796,000.00 | 59,099,000.00 | 0.00 | 228,000.00 | 0.00 | 0.00 | 34,164,000.00 | 34,164,000.00 | 12,791,000.00 | 0.00 | 12,791,000.00 | 11,683,000.00 | 11,683,000.00 | 0.00 | -13,000.00 | 11,683,000.00 | 0.00 | 0.00 | 937,707,000.00 | 533,000.00 | 10,184,000.00 | 136,179,000.00 | 136,179,000.00 | 478,000.00 | 12,266,000.00 | 761,377,000.00 | 0.00 | 0.00 | 16,690,000.00 | 16,690,000.00 | 125,000.00 | 16,690,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24,624,000.00 | 0.00 | 0.00 | 0.00 | -1,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 207,000.00 | 0.00 |
NSE: BALAXI Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repayment Of Debt | Issuance Of Debt | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Effect Of Exchange Rate Changes | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Net Preferred Stock Issuance | Preferred Stock Issuance | Net Common Stock Issuance | Common Stock Issuance | Net Issuance Payments Of Debt | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Dividends Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net Intangibles Purchase And Sale | Purchase Of Intangibles | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Capital Expenditure Reported | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Prepaid Assets | Change In Inventory | Change In Receivables | Other Non Cash Items | Depreciation And Amortization | Depreciation | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 32,967,000.00 | 0.00 | 60,402,000.00 | 257,901,000.00 | -15,694,000.00 | 622,859,000.00 | 1,000.00 | 282,121,000.00 | 0.00 | 340,737,000.00 | 302,539,000.00 | 433,000.00 | -15,259,000.00 | 0.00 | 0.00 | 0.00 | 257,901,000.00 | 257,901,000.00 | 60,402,000.00 | 60,402,000.00 | 0.00 | 60,402,000.00 | -10,463,000.00 | -1,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8,768,000.00 | -8,768,000.00 | -1,694,000.00 | 5,232,000.00 | -6,926,000.00 | 0.00 | 48,661,000.00 | -66,811,000.00 | 106,754,000.00 | 18,087,000.00 | -17,659,000.00 | -54,808,000.00 | -2,535,000.00 | 228,553,000.00 | -64,884,000.00 | -32,418,000.00 | 20,984,000.00 | 20,984,000.00 | 0.00 | 20,153,000.00 |
| 2023-03-31T00:00:00 | annual | -89,047,000.00 | 0.00 | 79,827,000.00 | 184,713,000.00 | -149,799,000.00 | 282,121,000.00 | 1,000.00 | 71,897,000.00 | 0.00 | 210,224,000.00 | 255,126,000.00 | -2,000.00 | -3,537,000.00 | -4,984,000.00 | 0.00 | 0.00 | 184,713,000.00 | 184,713,000.00 | 79,827,000.00 | 79,827,000.00 | 0.00 | 79,827,000.00 | -105,654,000.00 | -554,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -19,215,000.00 | -19,215,000.00 | -107,988,000.00 | 0.00 | -107,988,000.00 | -22,596,000.00 | 60,752,000.00 | -120,937,000.00 | -467,878,000.00 | 7,557,000.00 | -4,946,000.00 | -158,074,000.00 | 1,296,000.00 | -63,197,000.00 | -250,514,000.00 | 62,819,000.00 | 17,525,000.00 | 17,525,000.00 | 0.00 | 569,223,000.00 |
| 2022-03-31T00:00:00 | annual | 68,002,000.00 | -211,000.00 | 0.00 | 0.00 | -273,443,000.00 | 71,898,000.00 | -1,000.00 | 16,564,000.00 | 0.00 | 55,334,000.00 | -1,628,000.00 | -1,000.00 | -1,416,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -211,000.00 | -211,000.00 | -211,000.00 | 0.00 | -284,483,000.00 | -505,000.00 | 0.00 | 0.00 | 34,164,000.00 | 34,164,000.00 | 0.00 | -220,229,000.00 | -220,229,000.00 | -47,494,000.00 | 0.00 | -47,494,000.00 | -5,720,000.00 | 341,445,000.00 | -55,924,000.00 | -159,659,000.00 | -512,000.00 | -30,184,000.00 | 274,068,000.00 | -17,294,000.00 | -850,857,000.00 | 465,120,000.00 | 6,682,000.00 | 5,122,000.00 | 5,122,000.00 | 0.00 | 545,223,000.00 |
| 2021-03-31T00:00:00 | annual | -25,533,000.00 | 0.00 | 36,592,000.00 | 0.00 | -25,564,000.00 | 16,565,000.00 | 1,000.00 | 39,800,000.00 | 0.00 | -23,236,000.00 | 36,461,000.00 | 0.00 | -131,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36,592,000.00 | 36,592,000.00 | 0.00 | 36,592,000.00 | -59,728,000.00 | 0.00 | 0.00 | 0.00 | -34,164,000.00 | 0.00 | -34,164,000.00 | -12,791,000.00 | -12,791,000.00 | -12,773,000.00 | 0.00 | -12,773,000.00 | 0.00 | 31,000.00 | -25,947,000.00 | -411,390,000.00 | 707,000.00 | -15,499,000.00 | 191,462,000.00 | 1,472,000.00 | -127,858,000.00 | -461,674,000.00 | -8,902,000.00 | 2,978,000.00 | 2,978,000.00 | 0.00 | 443,292,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 255,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: BALAXI Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Net Income Including Noncontrolling Interests | Net Income Discontinuous Operations | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Depreciation Income Statement | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | -11.51 | 0.00 | 44.15 | -38.36 | -38.36 | -2.39 | 2.10 | 128.68 | 5.79 | 3.69 | -2.77 | 1.68 | 0.00 | 24.47 | -2.39 | 195.51 | 7.89 | 5.16 | 5.15 | 0.00 | 0.00 | -2.39 | -2.39 | 0.00 | -2.39 | -2.39 | 0.00 | -2.39 | 4.40 | 2.02 | 0.63 | -38.36 | 38.36 | 0.00 | -2.77 | 1.09 | 1.68 | 0.00 | 45.79 | 66.83 | 0.21 | 2.10 | 2.10 | 28.45 | 0.66 | 27.79 | 7.89 | 112.61 | 128.68 | 241.29 | 241.29 |
| 2023-03-31T00:00:00 | annual | 0.00 | 0.00 | 59.17 | 0.00 | 0.00 | 45.96 | 1.75 | 202.42 | 59.17 | 57.42 | -1.38 | 0.50 | 0.00 | 45.96 | 45.96 | 280.77 | 9.91 | 5.06 | 5.02 | 0.00 | 0.00 | 45.96 | 45.96 | 0.00 | 45.96 | 45.96 | 0.00 | 45.96 | 10.96 | 56.92 | 0.77 | 0.00 | 0.00 | 0.00 | -1.38 | 0.88 | 0.50 | 0.00 | 55.66 | 78.35 | 4.75 | 1.75 | 1.75 | 32.10 | 0.84 | 31.26 | 9.91 | 134.02 | 202.42 | 336.43 | 336.43 |
| 2022-03-31T00:00:00 | annual | 0.00 | 0.00 | 55.18 | 0.00 | 0.00 | 47.66 | 0.51 | 195.60 | 55.18 | 54.66 | -0.76 | 0.14 | 0.00 | 47.66 | 47.66 | 229.08 | 3.49 | 5.00 | 5.00 | 0.00 | 0.00 | 47.66 | 47.66 | 0.00 | 47.66 | 47.66 | 0.00 | 47.66 | 6.86 | 54.52 | 0.03 | 0.00 | 0.00 | 0.00 | -0.76 | 0.62 | 0.14 | 0.00 | 50.31 | 33.48 | 2.37 | 0.51 | 0.51 | 14.16 | 1.02 | 13.14 | 3.49 | 83.79 | 195.60 | 279.39 | 279.39 |
| 2021-03-31T00:00:00 | annual | -0.01 | 0.00 | 44.68 | -0.04 | -0.04 | 38.14 | 0.30 | 172.15 | 44.65 | 44.35 | -0.28 | 0.02 | 0.00 | 38.17 | 38.14 | 188.92 | 1.21 | 5.00 | 5.00 | 0.00 | 0.00 | 38.14 | 38.14 | 0.00 | 38.14 | 38.14 | 0.00 | 38.14 | 6.19 | 44.33 | 0.18 | -0.04 | 0.00 | 0.04 | -0.28 | 0.26 | 0.02 | 0.00 | 42.42 | 16.77 | 0.65 | 0.30 | 0.30 | 5.66 | 0.10 | 5.56 | 1.21 | 59.19 | 172.15 | 231.33 | 231.33 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
6/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
6.82
P/E
11.178885
P/B
1.9296381
Dividend Yield
N/A
Market Cap
388.11 Cr.
Face Value
39.51
Book Value
39.51
ROE
-0.99%
EBITDA Growth
46.73 Cr.
Debt/Equity
9.636
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of balaxi?
The market capitalization of Balaxi Pharmaceuticals Limited is ₹388 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Balaxi Pharmaceuticals Limited?
The PE and PB ratios of Balaxi Pharmaceuticals Limited are Not Available and 1.9296381 respectively as of 05 Feb 2025.
What is the 52 Week High of Balaxi Pharmaceuticals Limited?
The 52-week high of Balaxi Pharmaceuticals Limited is ₹151.45 as of 05 Feb 2025.
What is the 52 Week Low of Balaxi Pharmaceuticals Limited?
The 52-week low of Balaxi Pharmaceuticals Limited is ₹73.35 as of 05 Feb 2025.
What are the earnings per share (EPS) for Balaxi Pharmaceuticals Limited?
The Earnings Per Share (EPS) of Balaxi Pharmaceuticals Limited is ₹6.82 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Balaxi Pharmaceuticals Limited?
The Return on Equity (ROE) of Balaxi Pharmaceuticals Limited is -0.99% as per the most recent financial year data. Explore more on Fincept.